STOCK TITAN

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

Rhea-AI Summary
Eli Lilly and Company announces a dividend of $1.13 per share for the fourth quarter of 2023, payable on Dec. 8, 2023, to shareholders of record on Nov. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
dividends
-
Rhea-AI Summary
Eli Lilly's Omvoh receives FDA approval for the treatment of ulcerative colitis, achieving primary and secondary endpoints in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
fda approval
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Eli Lilly and Company to announce Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
earnings
-
Rhea-AI Summary
Eli Lilly announces five-year outcomes from the monarchE study, showing the long-term benefits of adjuvant Verzenio treatment in patients with early breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary
Patients with moderate-to-severe atopic dermatitis who continued treatment with lebrikizumab for up to two years experienced sustained skin clearance and itch relief, according to the ADjoin long-term extension study. Lebrikizumab is an interleukin-13 inhibitor that specifically blocks IL-13 signaling. The study showed durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing. The safety profile of lebrikizumab was consistent with previous studies, with no new safety signals observed. Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Eli Lilly's tirzepatide shows significant weight loss in SURMOUNT-3 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
Mirikizumab demonstrates positive results in Phase 3 trial for Crohn's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
clinical trial
Rhea-AI Summary
Eli Lilly and Company to present data on Verzenio, Retevmo, and imlunestrant at the 2023 ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

739.87B
897.86M
0.16%
84.35%
0.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.